Announcements Trials

Conditions

Lymphoid 3Other 1

Drug Classes

Anti-CD19 CAR T-cell 14Anti-CD20 14BTK inhibitor 13Anti-CD20-CD3 bispecific 5Anti-CD30 ADC 5Immunomodulatory drugs (IMiDs) 5Anti-PD-1 4Bcl-2 inhibitor 4Nitrogen mustard 3PI3K delta inhibitor 3Anthracycline 2Anti-CD19 2Anti-CD19-CD3 bispecific 2Anti-CD22 ADC 2Anti-CD79B ADC 2Asparagine-specific enzyme 2ALK inhibitor 1Anti-CCR4 1Anti-CD19 ADC 1Anti-CD22 immunotoxin 1Bcr-Abl inhibitor 1EZH inhibitor 1FGFR inhibitor 1HDAC inhibitor 1KMT2A inhibitor 1Proteasome inhibitor 1XPO1 inhibitor 1
PI3K delta inhibitor × Lymphoid × Clear all

3 Announcements

2021-02-05

FDA grants accelerated approval to umbralisib for marginal zone lymphoma and follicular lymphoma

Trial
UNITY-NHL
Drug
Ukoniq (umbralisib) · PI3K delta inhibitor
Condition
Lymphoid
2018-09-24

duvelisib (COPIKTRA, Verastem, Inc.) for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)

Trial
DYNAMO + R
Drug
COPIKTRA (duvelisib) · PI3K delta inhibitor
Conditions
LymphoidOther hematologic neoplasm
2017-09-14

FDA grants accelerated approval to copanlisib for relapsed follicular lymphoma

Drug
ALIQOPA (copanlisib) · PI3K delta inhibitor
Condition
Lymphoid
Data powered by HemOnc (CC BY 4.0) Colophon âš¡